Nuvectis Pharma Inc (NAS:NVCT)
$ 5.22 0.2 (3.98%) Market Cap: 96.99 Mil Enterprise Value: 72.67 Mil PE Ratio: 0 PB Ratio: 9.15 GF Score: 20/100

Nuvectis Pharma Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 12:30AM GMT
Release Date Price: $10.2 (+0.59%)
Elizabeth Ugeda J.P. Morgan Chase;Co.;Moderator

&-

Everyone. This is Elizabeth. You got and I'm a member of the JPMorgan Healthcare Investment Banking team. And it is my pleasure to welcome you all here today and to introduce our speaker of Novartis Pharma, CEO, Ron Bentsur, you take it.

Ron Bentsur Nuvectis Pharma
Inc. - CEO

Thank you very much, Elizabeth. And I want to thank JPMorgan for inviting us to present at this very important conference and I want to thank all of you here in attendance. It's a pleasure to be here. So I'm going to talk about in effect this pharma, and we're focused on precision medicine for serious conditions of unmet medical need in oncology, and I will be making some forward-looking statements. So I do encourage anyone who's interested in the Company to read our public disclosures and in particular the risk factors that appear in our 2210 K. So it's very important that you do that as you if you decide to dig in deeper. So by way of some of some key highlights. As I said, we're focused on precision medicine

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot